OGN

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported first-quarter profit of $146 million. The Jersey City, New Jersey-based company said it had net income of 55 cents per share. Earnings, adjusted for one-time gains and costs, were 71 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 83 cents per share. The pharmaceutical company posted revenue of $1.46 billion in the period, also falling short of Street forecasts. Three analysts surveyed by Zacks expected $1.47 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OGN at https://www.zacks.com/ap/OGN

First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. In light of the pending merger, Organon will not be providing financial guidance or hosting quarterly earnings calls. JERSEY CITY, N.J., April 30, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue For the first quarter of 2026, total revenue was $1.460 billion, down 4% on an as-reported basis and down 9% excluding the impact of foreign currency (ex-FX), compared with the first quarter of 2025. Women’s Health revenue declined 16% as-reported and declined 19% ex-FX in the first quarter of 2026, compared with the first quarter of 2025. Sales of Nexplanon® (etonogestrel implant) decreased 21% ex-FX in the first quarter compared with the first quarter of 2025. In the U.S., sales of Nexplanon declined 28% primarily due to both decreased physician demand following the five-year label approval which as expected, has delayed reinsertions; and continued uncertainty around federal funding. Outside of the U.S., Nexplanon sales declined 4% ex-FX, due to the timing of shipments in selective emerging markets, partially offset by increased demand and access in Brazil. Sales of oral contraceptives MarvelonTM (desogestrel and ethinyl estradiol pill) and MercilonTM (desogestrel and ethinyl estradiol pill) declined 36% ex-FX in the first quarter of 2026 primarily due to decreased demand and market contraction in China and the timing of shipments in Asia Pacific. Global Fertility revenue was down 9% ex-FX as a result of competition-driven price reductions in the U.S. partially offset by modest market growth in China. In January...

Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.87%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.73 per share when it actually produced earnings of $0.63, delivering a surprise of -13.7%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Organon, which belongs to the Zacks Medical Services industry, posted revenues of $1.46 billion for the quarter ended March 2026, missing the Zacks Consensus Estimate by 0.48%. This compares to year-ago revenues of $1.51 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Organon shares have added about 86.1% since the beginning of the year versus the S&P 500's gain of 4.2%. While Organon has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Organon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It wil...

For the quarter ended March 2026, Organon (OGN) reported revenue of $1.46 billion, down 3.5% over the same period last year. EPS came in at $0.71, compared to $1.02 in the year-ago quarter. The reported revenue represents a surprise of -0.48% over the Zacks Consensus Estimate of $1.47 billion. With the consensus EPS estimate being $0.83, the EPS surprise was -14.87%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Established Brands- U.S.- Respiratory- Other: $11 million versus the three-analyst average estimate of $9.57 million. The reported number represents a year-over-year change of +10%. Revenue- Women's Health- Int'l- Nexplanon/Implanon NXT: $74 million compared to the $78.51 million average estimate based on three analysts. The reported number represents a change of +2.8% year over year. Revenue- Women's Health- U.S.- NuvaRing: $6 million versus the three-analyst average estimate of $3.51 million. The reported number represents a year-over-year change of 0%. Revenue- Women's Health- Int'l- Follistim AQ: $39 million versus $35.59 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.7% change. Revenue- Women's Health- Nexplanon/Implanon NXT: $201 million compared to the $219.22 million average estimate based on three analysts. The reported number represents a change of -19% year over year. Revenue- Established Brands Total: $880 million versus $868.4 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change. Revenue- Women's Health- NuvaRing: $24 million versus $19.75 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change. Revenue- Women's Health- Follistim AQ: $61 million versus $67.09 million estimated by three...

JERSEY CITY, N.J., April 29, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company’s April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC"). About Organon Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook. Cautionary Note Regarding Forward-Looking Statements Except for historical information, this press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, Organon’s proposed merger with Sun Pharmaceutical Industries Limited and the timing of Organon’s release of first quarter 2026 financial information. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking s...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

JERSEY CITY, N.J., April 16, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the first quarter of 2026. Organon’s first quarter results have not been finalized and are subject to the company’s quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing First Quarter 2026 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website. Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144 (U.S. and Canada Toll-Free) or (646) 968-2525 and using the access code Conference ID: 1036555#. About Organon Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook. Cautionary Note Regarding Forward-Looking Statements The information above reflects management’s current intentions and expectations for the future with respect to Organon’s expectations regarding milestone expenses, which constitute "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are subject to a number of risks, assumptions, uncertainties and other factors, such as the...

NEW YORK, March 16, 2026 /PRNewswire/ -- Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, March 20, 2026, the Index will be rebalanced, and the following changes will be effective. For additional information, please visit www.lseg.com. Unlock Your Growth Potential with Alger Founded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a suite of growth equity separate accounts, mutual funds, ETFs, and privately offered investment vehicles. Alger's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for more than 60 years. For more information, please visit www.alger.com. Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases and similar public health threats, recessions, or other events could have a significant impact on investments. This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities. Alger pays compensation to third party marketers to sell various strategies to prospective investors. London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). ﾩ LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSEﾮ" "Russellﾮ", "FTSE Russellﾮ" are trade marks of the relevant LSE Group companies and are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the...

Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of exclusivity for key drugs like Atozet, and policy-related headwinds for Nexplanon in the U.S. as major drivers of the year-on-year revenue decline. Interim CEO Joe Morrissey emphasized that biosimilars, particularly Hadlima, and new product launches provided some offset, but cost containment efforts and product mix shifts could not fully mitigate gross margin compression. CFO Matthew Walsh described the gross margin decline as “primarily driven by pricing pressure and unfavorable product mix.” Is now the time to buy OGN? Find out in our full research report (it’s free). Revenue: $1.51 billion vs analyst estimates of $1.51 billion (5.3% year-on-year decline, in line) Adjusted EPS: $0.63 vs analyst expectations of $0.73 (13.3% miss) Adjusted EBITDA: $383 million vs analyst estimates of $390.2 million (25.4% margin, 1.8% miss) EBITDA guidance for the upcoming financial year 2026 is $1.9 billion at the midpoint, in line with analyst expectations Operating Margin: 14.4%, down from 18.1% in the same quarter last year Market Capitalization: $1.94 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Umer Raffat (Evercore ISI) questioned the thoroughness of the company’s internal investigations into channel behavior issues. Board Chair Carrie Cox declined further comment, citing the sensitivity of ongoing matters. Michael Nedelcovych (TD Cowen) asked about the impact of recent FDA biosimilar guidance and Nexplanon’s 2026 contribution. Interim CEO Joe Morrissey described changes as “incremental,” while CFO Matthew Walsh expects Nexplanon sales to remain roughly flat, balancing ex-U.S. growth with U.S. headwinds. Bhavin Patel (Bank of America) pressed management on whether cost savings were offsetting underlying EBITDA declines and on the potential for Nexplanon REMS program friction. Walsh said savings were reinvested in growth, and R&D head Juan Camilo Ferreira expressed confidence in the recertification process limiting disrup...

In February 2026, Organon & Co. reported fourth-quarter 2025 results showing sales of US$1,507 million, a net loss of US$205 million versus a profit a year earlier, weaker earnings per share, nearly flat full-year 2025 sales at US$6,216 million, and issued 2026 revenue guidance of about US$6.2 billion while affirming a US$0.02 quarterly dividend. Alongside the earnings miss and margin pressure, Organon highlighted FDA approval to extend Nexplanon’s duration to five years and the completed Jada divestiture, with about US$390 million in proceeds earmarked for debt reduction, underlining both product-transition challenges and efforts to strengthen the balance sheet. We’ll now examine how Organon’s earnings miss and flat 2026 revenue outlook reshape the earlier investment narrative built on gradual improvement. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource. To own Organon today, you need to believe that women’s health, biosimilars, and newer launches can eventually offset pressure on legacy products and margins. The Q4 2025 earnings miss, net loss, and flat 2026 revenue guidance sharpen the main near term catalyst and risk: whether management can stabilize profitability while generic and pricing headwinds persist. For now, the latest results reinforce, rather than change, that execution risk around margins is front and center. The most relevant recent announcement here is Organon’s 2026 revenue guidance of about US$6.2 billion, essentially flat with 2025’s US$6,216 million. That outlook, paired with weaker earnings and significant margin compression, directly challenges earlier expectations for gradual improvement, even as product moves like the Nexplanon 5 year label extension and the Jada sale aim to support longer term repositioning. But beneath the low headline revenue growth, one risk investors should be aware of is how much ongoing pricing pressure and loss of exclusivity could... Read the full narrative on Organon (it's free!) Organon's narrative projects $6.5 billion revenue and $990.3 million earnings by 2028. This requires 1.2% yearly revenue growth and a $290.3 million earnings increase from $700.0 milli...

Image source: The Motley Fool. Feb. 12, 2026 at 8:30 a.m. ET Interim Chief Executive Officer — Joseph Morrissey Chief Financial Officer — Matthew Walsh Board Chair — Carrie Cox Head of R&D — Juan Camilo Arjona Ferreira Jennifer Halchak: Thank you, operator. Good morning, everyone. With me today are Joe Morrissey, Organon's Interim Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Carrie Cox, Organon's Board Chair; and Juan Camilo Arjona Ferreira, Organon's Head of R&D, will also be joining for the Q&A portion of this call. Today, we are referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentations section of our Organon Investor Relations website. Please reference Slides 2 and 3 for a couple of brief reminders. I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as potential, should, will, continue, expects, believe, future, estimates, believes, outlook and other words of similar meaning. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with the Securities and Exchange Commission. This includes our most recent Form 10-K and Forms 10-Q and those amended forms. These statements are based on information as of today, February 12, 2026 and except as required by law, Organon undertakes no obligation to update or revise any of these forward-looking statements. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. Descriptions of these measures and reconciliations to the comparable GAAP measures are included in today's earnings press release and conference call presentation, both of which are available on our Investor Relations website and have been furnished to the SEC on the current report on Form 8-K. I note that while our full year 2026 guidance measures other than revenue are provided on a non-...